Similar results were seen in an adoptive T-cell transfer study to treat human lung cancer, where dual blockade of TIGIT/PD-1 or TIM-3/PD-1 resulted in greater tumor control than PD-1 monotherapy (127). The gene discussed is HAVCR2; the disease is neoplasm.